Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

MRT5500

- PMLiVE

Pfizer/BioNTech submit FDA application for Omicron-adapted booster for young children

The vaccine is already authorised as the third of a three-dose primary series in this age group

- PMLiVE

Rare Disease Day 2023 – raising awareness around the world

Around one in 17 people will be affected by a rare disease at some point in their lives

- PMLiVE

Sanofi reports positive new data for multiple sclerosis treatment tolebrutinib

It is estimated that there are over 130,000 people living with the condition in the UK alone

- PMLiVE

FDA authorises first at-home COVID-19 and flu test for emergency use

The single-use test uses nasal swab samples and provides results in about 30 minutes

- PMLiVE

Sanofi and Sobi’s once-weekly haemophilia A treatment approved by FDA

Current factor VIII therapies usually require patients to receive treatment every two days

- PMLiVE

Gilead reports positive real-world evidence for COVID-19 treatment Veklury

A study of more than 500,000 hospitalised patients showed a reduction in mortality risk

- PMLiVE

AstraZeneca/Sanofi’s Beyfortus shows consistent protection against RSV disease in infants

RSV is the most common cause of infant respiratory infections, including pneumonia

- PMLiVE

Merck and Ridgeback’s COVID-19 pill fails to prevent infection within households

Lagevrio is already approved to treat certain patients with COVID-19 in several markets

- PMLiVE

AstraZeneca’s Evusheld not recommended by NICE for COVID-19 prevention

The agency said there is not enough evidence of the drug’s effectiveness against current variants

- PMLiVE

GSK and Vir Biotech amend COVID-19 research partnership

Vir will now advance new antibodies and vaccines for COVID-19 alone or with other partners

- PMLiVE

Eiger BioPharmaceuticals reports positive phase 3 results for COVID-19 treatment

Peginterferon lambda showed a 51% reduction in hospitalisations or emergency room visits

- PMLiVE

Sanofi’s enzyme replacement therapy available on NHS to Pompe disease patients

The rare genetic disorder affects around one in every 40,000 people in the UK

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links